World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Original Article

Volume 15, Number 2, April 2024, pages 309-318

Role of Postoperative Radiotherapy on High-Risk Stage pIIIA-N2 Non-Small Cell Lung Cancer Patients After Complete Resection and Adjuvant Chemotherapy: A Retrospective Cohort Study

Figures

Figure 1.
Figure 1. Flowchart illustrating the patient selection process for the study, outlining the criteria for inclusion and exclusion from the Surveillance, Epidemiology, and End Results database. SCC: squamous cell carcinoma. AC: adenocarcinoma.
Figure 2.
Figure 2. Graphs showing the association between lymph node ratio and survival outcomes, which are analyzed using restricted cubic spline regression models. (a) Cancer-specific survival. (b) Overall survival. HR: hazard ratio; CI: confidence interval.
Figure 3.
Figure 3. Kaplan-Meier survival curves comparing cancer-specific survival and overall survival between patients categorized by lymph node ratio: those with lymph node ratio < 0.29 versus lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Data on overall survival. LNR: lymph node ratio; HR: hazard ratio; CI: confidence interval.
Figure 4.
Figure 4. Results of multivariate regression analysis assessing various prognostic factors impacting treatment outcomes. (a) Cancer-specific survival. (b) Overall survival. LNR: lymph node ratio.
Figure 5.
Figure 5. Kaplan-Meier survival curves depicting treatment outcomes between non-radiotherapy and radiotherapy groups in patients with lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Overall survival. HR: hazard ratio; CI: confidence interval.
Figure 6.
Figure 6. Multivariate regression analysis evaluating various prognostic factors for treatment outcomes in patients with lymph node ratio ≥ 0.29. (a) Cancer-specific survival. (b) Overall survival. LNR: lymph node ratio.

Tables

Table 1. Patient Characteristics Between Different Lymph Node Ratio Groups
 
LNR < 0.29 (n = 840)LNR ≥ 0.29 (n = 850)P
LNR: lymph node ratio.
Age0.440
  < 66418 (49.8%)406 (47.8%)
  ≥ 66422 (50.2%)444 (52.2%)
Sex0.133
  Female419 (49.9%)456 (53.6%)
  Male421 (50.1%)394 (46.4%)
Race0.779
  White696 (82.8%)695 (81.8%)
  Black72 (8.6%)81 (9.5%)
  Others72 (8.6%)74 (8.7%)
Site0.959
  Upper lobe480 (57.1%)476 (56.0%)
  Middle lobe48 (5.7%)50 (5.9%)
  Lower lobe287 (34.2%)300 (35.3%)
  Others25 (3.0%)24 (2.8%)
Laterality0.650
  Left358 (42.6%)352 (41.4%)
  Right482 (57.4%)498 (58.6%)
Grade0.712
  I/II421 (50.1%)409 (48.1%)
  III/IV350 (41.7%)369 (43.4%)
  unknown69 (8.2%)72 (8.5%)
Histology0.002
  Squamous cell carcinoma625 (74.4%)687 (80.8%)
  Adenocarcinoma215 (25.6%)163 (19.2%)
T stage0.783
  T1283 (33.7%)280 (32.9%)
  T2557 (66.3%)570 (67.1%)

 

Table 2. Patient Characteristics Between Non-Radiotherapy and Radiotherapy Groups in Patients With Lymph Node Ratio ≥ 0.29
 
Non-radiotherapy (n = 376)Radiotherapy (n = 474)P
Age0.037
  < 66164 (43.6%)242 (51.1%)
  ≥ 66212 (56.4%)232 (48.9%)
Sex0.507
  Female207 (55.1%)249 (52.5%)
  Male169 (44.9%)225 (47.5%)
Race0.097
  White314 (83.5%)381 (80.4%)
  Black38 (10.1%)43 (9.1%)
  Others24 (6.4%)50 (10.5%)
Site0.537
  Upper lobe206 (54.8%)270 (57.0%)
  Middle lobe23 (6.1%)27 (5.7%)
  Lower lobe133 (35.4%)167 (35.2%)
  Others14 (3.7%)10 (2.1%)
Laterality0.502
  Left161 (42.8%)191 (40.3%)
  Right215 (57.2%)283 (59.7%)
Grade0.635
  I/II178 (47.3%)231 (48.7%)
  III/IV169 (44.9%)200 (42.2%)
  Unknown29 (7.8%)43 (9.1%)
Histology0.441
  Squamous cell carcinoma299 (79.5%)388 (81.9%)
  Adenocarcinoma77 (20.5%)86 (18.1%)
T stage0.350
  T1117 (31.1%)163 (34.4%)
  T2259 (68.9%)311 (65.6%)